How is Ocriplasmin used in foreign markets?

Ocriplasmin (Ocriplasmin) was approved by the US FDA for marketing in October 2012, and has been mainly used to treat vitreous-macular adhesion and small macular holes. Its marketed specification is 2.5 mg/mL injection, which uses minimally invasive intravitreal injection to provide non-surgical treatment options. Although it has not yet been approved for marketing in China and has not been included in medical insurance, the application of Jetrea in overseas markets has been relatively mature and has become one of the important means for the treatment of VMA-related diseases.

In the U.S. and European markets,Jetrea is mainly targeted at adult patients with clear vitreous-macular adhesion or macular hole. Clinicians confirm the type of lesion and degree of vitreous traction through optical coherence tomography (OCT), and select suitable patients for microinjection. Compared with traditional vitrectomy surgery, the advantages of Oak plasmin are less trauma, faster recovery, reduced surgery-related complications, and at the same time, it provides treatment opportunities for patients who are not suitable for surgery. Its clinical application emphasizes precise patient selection and imaging guidance to ensure the success rate of VMA dissociation and macular hole closure.

Jetrea has no generic drugs on the market in foreign markets, which means that all patients are using original drugs. The supply channels are concentrated and the price is relatively high, but the activity and safety of the drug are fully guaranteed. Clinically, patients usually require close follow-up after receiving injections to monitor changes in vision, fundus structure, and potential side effects, such as transient vision fluctuations, increased vitreous floaters, or changes in intraocular pressure. Long-term follow-up data shows that Oakplasmin can significantly improve anatomical structures and bring benefits to visual function in well-indicated patient groups.

In general, the application of Oak plasmin in foreign markets is focused onVMA and small macular hole treatment, providing patients with effective non-surgical options through minimally invasive enzymatic methods. Although it has not yet been launched in China, its international application experience and clinical data provide a reference for possible introduction into the domestic market in the future.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html